FIRST TR EXCHANGE-TRADED FD - NY ARCA BIOTECH (FBT)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / NY ARCA BIOTECH
Symbol
FBT
Price per share
$206.52
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
3,031,905
Total reported value
$544,022,410
% of total 13F portfolios
0%
Share change
-77,476
Value change
-$12,934,226
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
250
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
As of 30 Sep 2025, FIRST TR EXCHANGE-TRADED FD - NY ARCA BIOTECH (FBT) has 250 institutional shareholders filing 13F forms. They hold 3,031,905 shares. .

Institutional Holders of FIRST TR EXCHANGE-TRADED FD - NY ARCA BIOTECH (FBT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 56,845 $11,831,732 -$12,334 20,652.03% 14
2025 Q3 3,031,905 $544,022,410 -$12,934,226 17,929% 250
2025 Q2 3,155,408 $509,245,856 -$41,077,763 16,133% 247
2025 Q1 3,418,328 $576,824,224 +$1,866,805 17,011.5% 266
2024 Q4 3,418,857 $568,580,158 +$41,645,148 16,621% 253
2024 Q3 3,143,605 $540,228,542 -$50,274,497 17,193% 252
2024 Q2 3,468,418 $534,289,452 +$6,575,921 15,399% 247
2024 Q1 3,399,038 $522,621,545 -$94,532,990 15,377% 240
2023 Q4 4,017,594 $634,837,157 -$30,986,867 15,805.52% 254
2023 Q3 4,190,296 $613,262,596 -$62,820,801 14,634.95% 239
2023 Q2 4,617,487 $707,129,055 -$19,966,454 15,314% 247
2023 Q1 4,700,385 $728,635,260 -$18,428,171 15,502.82% 241
2022 Q4 4,877,768 $751,529,554 +$55,433,739 15,413% 239
2022 Q3 4,496,690 $593,813,874 +$22,209,350 13,198% 212
2022 Q2 4,332,609 $587,753,929 -$18,206,139 13,555.98% 218
2022 Q1 4,448,675 $663,407,924 -$82,106,064 14,913.81% 212
2021 Q4 4,955,742 $802,113,791 -$46,741,875 16,195.93% 239
2021 Q3 5,178,909 $859,978,174 -$14,178,042 16,606.26% 230
2021 Q2 5,220,166 $900,985,426 -$80,585,265 17,261.97% 227
2021 Q1 5,725,862 $919,195,735 -$21,822,779 16,049.84% 232
2020 Q4 5,809,688 $976,622,166 -$78,183,499 16,799.12% 232
2020 Q3 6,096,208 $959,021,765 -$32,144,151 15,726.04% 210
2020 Q2 6,226,658 $1,045,067,619 +$191,623,157 16,777% 222
2020 Q1 5,157,697 $676,659,157 -$47,084,204 13,111.81% 193
2019 Q4 5,487,562 $816,287,431 -$74,667,369 14,871.87% 207
2019 Q3 5,992,894 $742,538,774 -$882,858,217 12,376.13% 184
2019 Q2 12,569,930 $1,770,181,894 +$35,822,419 14,083.66% 217
2019 Q1 12,360,195 $1,864,503,721 +$128,595,965 15,085.06% 224
2018 Q4 11,657,169 $1,449,690,480 -$403,797,433 12,419.94% 190
2018 Q3 14,181,041 $2,246,741,087 +$1,432,250,063 15,849.02% 187
2018 Q2 5,133,431 $718,724,343 +$63,854,991 14,000.65% 154
2018 Q1 4,683,224 $622,474,212 +$91,611,191 13,289.85% 152
2017 Q4 3,984,755 $496,314,617 +$44,748,999 12,457.25% 126
2017 Q3 3,605,567 $446,754,001 +$14,480,513 12,393.02% 115
2017 Q2 3,492,182 $398,275,105 +$56,018,406 11,404% 112
2017 Q1 3,018,492 $316,695,674 -$4,736,324 10,530% 113
2016 Q4 3,095,489 $281,588,359 +$13,238,858 9,087.35% 107
2016 Q3 2,930,364 $291,496,084 -$4,711,885 9,970.61% 110
2016 Q2 3,076,251 $274,668,626 -$39,232,497 8,943.42% 105
2016 Q1 3,349,153 $294,129,961 -$1,892,206,413 8,755.98% 102
2015 Q4 21,779,226 $2,459,415,016 +$164,656,445 11,301.83% 127
2015 Q3 20,090,644 $2,036,625,833 +$162,029,493 10,131.88% 126
2015 Q2 18,456,703 $2,288,765,259 +$285,028,551 12,401.8% 123
2015 Q1 16,117,838 $1,905,196,132 +$443,224,811 11,823% 119
2014 Q4 12,339,312 $1,258,885,285 +$245,972,458 10,202% 109
2014 Q3 9,633,125 $883,813,866 +$85,577,040 9,177.99% 95
2014 Q2 8,789,399 $715,910,314 +$32,118,674 8,232.94% 92
2014 Q1 8,321,792 $638,198,251 +$51,685,578 7,669% 81